In a recent study published in the journal Cell Stem Cell, researchers hypothesized that pacemaker-like activity of human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) resulted in engraftment arrhythmias (EAs), which hampers the clinical use of cell-based therapy using hPSC-CMs for treatment of myocardial infarction (MI).
Study: Gene editing to prevent ventricular arrhythmias associated with cardiomyocyte cell therapy. Image Credit: FrentaN / Shutterstock.
Comments are closed.